Find Clinical Drug Pipeline Developments & Deals for Ifosfamide

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CypCaps,Ifosfamide

            Therapeutic Area: Oncology Product Name: CypCaps

            Highest Development Status: Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 02, 2020

            Details:

            The proposed Phase 2b study is intended to evaluate the efficacy and safety of CypCapsTM in combination with low doses of ifosfamide compared to chemoradiation therapy with capecitabine plus external beam radiation therapy or stereotactic body radiation therapy alone.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CypCaps,Ifosfamide

            Therapeutic Area: Oncology Product Name: CypCaps

            Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 05, 2020

            Details:

            The FDA’s Center for Biologics Evaluation and Research successfully processed PharmaCyte’s DMF, providing confidential and detailed information covering the production of the CypCaps™ will be used in PharmaCyte’s planned clinical trial in locally advanced pancreatic cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CypCaps,Ifosfamide

            Therapeutic Area: Oncology Product Name: CypCaps

            Highest Development Status: Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 10, 2020

            Details:

            PharmaCyte has successfully completed development of the “change history” information and data for CypCaps™ (2nd generation product) compared to CapCell™ (1st generation product).